Drug intelligence / Profile preview

Dharmanol

Development stage: Preclinical
Lead developer: Medical Greens
Administration: Oral

Overview

**Dharmanol** is a branded product distributed by Medical Greens, a subsidiary of SKTO (B. SKTO B.S. Medical Greens B.), launched for distribution as announced in a BioSpace press release. It is available in two forms: low-dose, non-psychoactive tablets and high-dose formulations targeted for cancer patients, suggesting potential applications in pain management or supportive cancer care, though specific indications, active ingredients, mechanism of action, or clinical data are not detailed in available sources.

Brand names: Dharmanol

Beyond the preview

Go deeper on Dharmanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dharmanol.

Explore the full profile